BioSpace News Archive

ORIC Pharmaceuticals, Inc., a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, reported financial results and operational updates for the quarter ended June 30, 2022.

ImmuCell Corporation, a growing animal health company that develops, manufactures and markets scientifically-proven and practical products that improve the health and productivity of dairy and beef cattle, announced its unaudited financial results for the quarter ended June 30, 2022.

HTG Molecular Diagnostics, Inc., a life science company advancing precision medicine through its innovative transcriptome-wide profiling technology, reported recent business highlights and financial results for the quarter ended June 30, 2022.

Beyond Air, Inc., a medical device and biopharmaceutical company focused on developing inhaled nitric oxide for the treatment of patients with respiratory conditions, including serious lung infections and pulmonary hypertension, and, through its affiliate Beyond Cancer, ultra-high concentration nitric oxide for the treatment of solid tumors, announced financial results for its first fiscal quarter ended June 30, 2022.

Adverum Biotechnologies, Inc., a clinical-stage company that aims to establish gene therapy as a new standard of care for highly prevalent ocular diseases, announced financial results for the second quarter ended June 30, 2022.

Kinnate Biopharma Inc., a clinical-stage precision oncology company, announced financial results for the quarter ended June 30, 2022, and recent corporate updates.

Opiant Pharmaceuticals, Inc., a specialty pharmaceutical company developing medicines to treat addictions and drug overdose, reported financial results for the three months and six months ended June 30, 2022, and provided a corporate update.

NeuroPace, Inc., a commercial-stage medical device company focused on transforming the lives of people suffering from epilepsy, reported financial results for the quarter ending June 30, 2022.

Eton Pharmaceuticals, Inc, an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, reported financial results for the second quarter ended June 30, 2022.

Larimar Therapeutics, Inc. announced that it has received meeting minutes from the U.S. Food and Drug Administration following a recent Type C Meeting with the Agency and reported its second quarter 2022 operating and financial results.